Despite suffering significant losses recently, biotechnology stocks and ETFs have seen some impressive gains over the last year or so, as coronavirus vaccines have propelled companies like Pfizer and Moderna to new heights. However, some analysts believe that the sector could have even more upside in store.
The post Could Biotech ETFs Be Due For More Upside? appeared first on ETF Trends.